BKM Wealth Management LLC Purchases 2,599 Shares of AstraZeneca PLC (NASDAQ:AZN)

BKM Wealth Management LLC increased its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 71.9% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 6,212 shares of the company’s stock after acquiring an additional 2,599 shares during the quarter. BKM Wealth Management LLC’s holdings in AstraZeneca were worth $421,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the company. Anchor Investment Management LLC acquired a new stake in AstraZeneca during the 4th quarter worth approximately $26,000. Compagnie Lombard Odier SCmA acquired a new stake in AstraZeneca during the 4th quarter worth approximately $27,000. Able Wealth Management LLC acquired a new stake in AstraZeneca during the 4th quarter worth approximately $27,000. Pin Oak Investment Advisors Inc. raised its holdings in AstraZeneca by 468.4% during the 4th quarter. Pin Oak Investment Advisors Inc. now owns 449 shares of the company’s stock worth $30,000 after buying an additional 370 shares during the period. Finally, Northwest Financial Advisors acquired a new stake in AstraZeneca during the 4th quarter worth approximately $34,000. Institutional investors own 20.35% of the company’s stock.

Analysts Set New Price Targets

Several analysts have commented on AZN shares. The Goldman Sachs Group started coverage on shares of AstraZeneca in a report on Thursday, May 30th. They set a “buy” rating and a $97.00 target price on the stock. Citigroup upgraded shares of AstraZeneca to a “strong-buy” rating in a report on Monday, June 24th. Argus raised their target price on shares of AstraZeneca from $80.00 to $85.00 and gave the stock a “buy” rating in a report on Thursday, May 30th. Deutsche Bank Aktiengesellschaft upgraded shares of AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, April 16th. Finally, BMO Capital Markets lifted their price objective on shares of AstraZeneca from $80.00 to $82.00 and gave the company an “outperform” rating in a report on Friday, April 26th. Three research analysts have rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $88.00.

AstraZeneca Price Performance

Shares of AZN opened at $77.94 on Tuesday. The company has a market cap of $241.65 billion, a price-to-earnings ratio of 38.21, a PEG ratio of 1.40 and a beta of 0.45. AstraZeneca PLC has a 1-year low of $60.47 and a 1-year high of $80.86. The company’s fifty day simple moving average is $77.68 and its 200 day simple moving average is $70.51. The company has a current ratio of 0.89, a quick ratio of 0.70 and a debt-to-equity ratio of 0.73.

AstraZeneca (NASDAQ:AZN) last issued its earnings results on Thursday, April 25th. The company reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $0.95 by $0.08. The business had revenue of $12.68 billion for the quarter, compared to the consensus estimate of $11.92 billion. AstraZeneca had a net margin of 13.30% and a return on equity of 30.42%. On average, research analysts forecast that AstraZeneca PLC will post 4.04 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.